Microsoft word - 12 saw palmetto.doc

Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia

A Systematic Review
Timothy J. Wilt, MD, MPH; Areef Ishani, MD; Gerold Stark, MD; Roderick MacDonald, MS; Joseph Objective.— To conduct a systematic review and, where possible, quantitative meta-analysis of
the existing evidence regarding the therapeutic efficacy and safety of the saw palmetto plant
extract, Serenoa repens , in men with symptomatic benign prostatic hyperplasia (BPH). Data Sources.— Studies were identified through the search of MEDLINE (1966-1997), EMBASE,
Phytodok, the Cochrane Library, bibliographies of identified trials and review articles, and contact
with relevant authors and drug companies. Study Selection.— Randomized trials were included if participants had symptomatic BPH, the
intervention was a preparation of S repens alone or in combination with other phytotherapeutic
agents, a control group received placebo or other pharmacological therapies for BPH, and the treatment duration was at least 30 days. Data Extraction.— Two investigators for each article (T.J.W., A.I., G.S., and R.M.) independently
extracted key data on design features, subject characteristics, therapy allocation, and outcomes of the studies. Data Synthesis.— A total of 18 randomized controlled trials involving 2939 men met inclusion
criteria and were analyzed. Many studies did not report results in a method that permitted meta-analysis. Treatment allocation concealment was adequate in 9 studies; 16 were double-blinded. The mean study duration was 9 weeks (range, 4-48 weeks). As compared with men receiving placebo, men treated with S repens had decreased urinary tract symptom scores (weighted mean difference [WMD], -1.41 points [scale range, 0-19] [95% confidence interval (CI), -2.52 to -0.30] [n=1 study]), nocturia (WMD, -0.76 times per evening [95% CI, -1.22 to -0.32] [n=10 studies]), and improvement in self-rating of urinary tract symptoms; risk ratio for improvement (1.72 [95% CI, 1.21-2.44] [n=6 studies]), and peak urine flow (WMD, 1.93 mL/s [95% CI, 0.72-3.14] [n=8 studies]). Compared with men receiving finasteride, men treated with S repens had similar improvements in urinary tract symptom scores (WMD, 0.37 International Prostate Symptom Score points [scale range, 0-35] [95% CI, -0.45 to 1.19] [n=2 studies]) and peak urine flow (WMD, -0.74 mL/s [95% CI, -1.66 to 0.18] [n=2 studies]). Adverse effects due to S repens were mild and infrequent; erectile dysfunction was more frequent with finasteride (4.9%) than with S repens (1.1%; P <.001). Withdrawal rates in men assigned to placebo, S repens, or finasteride were 7%, 9%, and 11%, respectively. Conclusions.— The existing literature on S repens for treatment of BPH is limited in terms of the
short duration of studies and variability in study design, use of phytotherapeutic preparations, and reports of outcomes. However, the evidence suggests that S repens improves urologic symptoms and flow measures. Compared with finasteride, S repens produces similar improvement in urinary tract symptoms and urinary flow and was associated with fewer adverse treatment events. Further research is needed using standardized preparations of S repens to determine its long-term effectiveness and ability to prevent BPH complications. From the Department of Veterans Affairs Coordinating Center of the Cochrane Collaborative Review Group in Prostatic Diseases and Urologic Malignancies and Minneapolis/Veterans Integrated Service Network 13 Center for Chronic Diseases Outcomes Research, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minn (Drs Wilt, Ishani, and Stark and Mr MacDonald); New England Medical Center, Boston, Mass (Dr Lau); and the Department of Veterans Affairs San Antonio Cochrane Center, San Antonio, Tex (Dr Mulrow). THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Proven and Unproven Therapy for Benign Prostatic Hyperplasia
DiPaola and Morton
Access To Conventional Medical Care And The Use Of Complementary And Alternative
Pagan and Pauly
Health Aff (Millwood) 2005;24:255-262. ABSTRACT | FULL TEXT Phytochemical Assays of Commercial Botanical Dietary Supplements
Krochmal et al. Evid Based Complement Alternat Med 2004;1:305-313. ABSTRACT | FULL TEXT Current Management of Urinary Incontinence
Journal of Pharmacy Practice 2004;17:103-114.
Internet Marketing of Herbal Products
Morris and Avorn
JAMA 2003;290:1505-1509. ABSTRACT | FULL TEXT Advising Patients Who Seek Complementary and Alternative Medical Therapies for
Weiger et al.
ANN INTERN MED 2002;137:889-903. ABSTRACT | FULL TEXT Tomatoes, Lycopene, and Prostate Cancer: Progress and Promise
Hadley et al. Exp. Biol. Med. 2002;227:869-880. Potential Physician Malpractice Liability Associated with Complementary and Integrative
Medical Therapies

Cohen and Eisenberg ANN INTERN MED 2002;136:596-603. Dietary Supplement Use: Consumer Characteristics and Interests
J. Nutr. 2001;131:1339S-1343. ABSTRACT | FULL TEXT Research into complementary and alternative medicine: problems and potential
Nahin and Straus
BMJ 2001;322:161-164.
Herbal medicines: where is the evidence?
Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy
and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer
Messing et al.
NEJM 1999;341:1781-1788. ABSTRACT | FULL TEXT Saw Palmetto for Benign Prostatic Hyperplasia
McKinney JAMA 1999;281:1699-1699. Urology
Alternative Medicine Meets Science
Fontanarosa and Lundberg JAMA 1998;280:1618-1619.


Microsoft word - 31405df0.docx

Marital Status:  Single Married Divorced Widowed Separated Source of referral: Self referred  Physician/Provider Other Referring/Primary Care Provider and telephone number:  White  American Indian/Alaska Native  Asian  Native Hawaiian/Pacific Islander  Spanish/Latino/Hispanic  Please describe your reason(s) for Meeting with the Dietitian today: ___

Updates to your prescription benefits Effective January 1, 2014 Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill a prescription. Please reference this chart as you review the following updates. Most options listed are available in Tier 1, your lowest cost option. If your medica

Copyright © 2010-2014 Internet pdf articles